Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 4805
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9,...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell